SASalvador Atilano-Miguel

Salvador Atilano-Miguel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Salvador Atilano-Miguel has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Lourdes Barbosa-Cortés

    Unidad de Investigación Médica en Nutrición, Unidad Médica de Alta Especialidad, Hospital de Pediatría "Dr. Silvestre Frenk Freund," Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social, Ciudad de México, México

    8 shared publications
  • Jorge Maldonado-Hernández

    Unidad de Investigación Médica en Nutrición, Unidad Médica de Alta Especialidad (UMAE), Instituto Mexicano del Seguro Social (IMSS), Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Ciudad de México 06720, Mexico

    5 shared publications
  • Karina Anastacia Solís-Labastida

    Departamento Clínico de Hematología, Unidad Médica de Alta Especialidad (UMAE), Instituto Mexicano del Seguro Social (IMSS), Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Ciudad de México 06720, Mexico

    5 shared publications
  • Azalia Juárez-Moya

    Departamento Clínico de Hematología, Unidad Médica de Alta Especialidad (UMAE), Instituto Mexicano del Seguro Social (IMSS), Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Ciudad de México 06720, Mexico

    4 shared publications
  • Benito A. Bautista-Martínez

    Departamento Clínico de Hematología, Unidad Médica de Alta Especialidad (UMAE), Instituto Mexicano del Seguro Social (IMSS), Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Ciudad de México 06720, Mexico

    4 shared publications
  • Jorge Alfonso Martín-Trejo

    Servicio de Hematología, Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México 06600, Mexico

    4 shared publications

Latest Publications

  • Open Access

    Clinical outcomes in pediatric acute lymphoblastic leukemia using modified BFM-95 protocol: 10-year study in Mexico city.

    by Karina A Solis-Labastida, Rosa E Valdez-Avilez, Salvador Atilano-Miguel, Jorge A Martin-Trejo, Lourdes Barbosa-Cortés, Benito A Bautista-Martínez, Azalia Juárez-Moya, Zayra Hernández-Piñón

    Although survival rates for acute lymphoblastic leukemia (ALL) in developed countries have reached up to 80%, outcomes remain considerably lower in emerging nations. This study aimed to evaluate the 10-year survival of pediatric patients with ALL treated at a public hospital using the HP 09 protocol, adapted from the BFM 95 protocol. We included patients under 17 years of age diagnosed with ALL and treated with the HP 09 protocol between January 2010 and December 2020. Patients were stratified into three risk groups according to clinicobiological characteristics. A total of 253 patients were analyzed. The cohort demonstrated a 10-year overall survival (OS) rate of 58.1% (90.4 ± 4.8 months) and an event-free survival (EFS) rate of 56.9% (78.2 ± 5.0 months). By risk group, the 10-year OS was 41% in the high-risk group, 61.9% in the intermediate-risk group, and 85.7% in the standard-risk group. Corresponding 10-year EFS rates were 55.2%, 57.1%, and 59.7%. Cox regression analysis identified older age (>10 years; OR 2.11, CI 1.36 to 3, P=.001), leukocyte count >50 × 109/L (OR 1.89, CI 1.22 to 2.93, P=.004), and prior steroid exposure before diagnosis (OR 2.30, CI 1.16 to 4.58, P=.017) as significant predictors of relapse. This study highlights a substantial disparity in survival rates among pediatric patients with ALL in Mexico compared with international benchmarks. The gap likely reflects differences in chemotherapy efficacy, disease biology, and systemic healthcare limitations.

  • Open Access

    Relación entre la dosis acumulada de glucocorticoides y las concentraciones de vitamina D sobre los cambios en el cociente RANKL/OPG en niños con leucemia linfoblástica aguda en tratamiento

    by Salvador Atilano Miguel

    Mexico City has one of the highest rates of acute lymphoblastic leukemia (ALL) reported in the world, with 55 to 59 cases per million children under 14 years old. In pediatric patients with ALL, th...

  • Open Access

    Impact of Omega-3 and Vitamin D Supplementation on Bone Turnover Markers in Children with Leukemia: Follow-Up During and After Supplementation

    by Lourdes Barbosa-Cortés, Sharon B. Morales-Montes, Michelle Maldonado-Alvarado, Jorge A. Martin-Trejo, Salvador Atilano-Miguel, Emmanuel Jiménez-Aguayo, Fabián I. Martínez-Becerril, Víctor M. Cortés-Beltrán, Atzin V. Hernández-Barbosa, Karina A. Solís-Labastida, et al.

    Background/Objective: In patients with acute lymphoblastic leukemia (ALL), it has been demonstrated that the treatment has a negative effect on bone health. The n-3 polyunsaturated fatty acids (LCPUFAs-ω3) may attenuate bone resorption. We evaluated the effects of LCPUFAs-ω3, vitamin D, and calcium supplementation on bone turnover markers and changes in vitamin D concentrations during 6 weeks of supplementation and during 6 weeks of post-intervention follow-up in pediatric patients with ALL. Methods: Thirty-six pediatric patients with ALL were randomly assigned to the ω-3VDCa group (100 mg/kg/d LCPUFAs-ω3 + 4000 IU vitamin D + 1000 mg calcium) or the VDCa group (4000 IU vitamin D + 1000 mg calcium) for 6 weeks. Blood samples were collected to determine 25(OH)D, PTH, ICTP, and TRAP-5b (biomarkers of bone resorption) and osteocalcin (OC, a biomarker of bone production) levels at baseline, 6 weeks, and 12 weeks after supplementation. The 25(OH)D analysis was performed using ultra-high-performance liquid chromatography coupled to a mass spectrometer, and PTH and bone turnover markers were measured by ELISA. Results: The 25(OH)D concentration increased in both groups (ω3VDCa group: 19.4 ng/mL vs. 44.0 ng/mL, p < 0.0001; VDCa group: 15.3 ng/mL vs. 42.8 ng/mL, p = 0.018) and remained significantly higher at 12 weeks. At 12 weeks, ICTP showed lower concentrations in the ω-3VDCa group than in the VDCa group (0.74 ng/mL vs. 1.05 ng/mL, p = 0.024). Conclusions: Combined omega-3 and 4000 IU vitamin D supplementation for 6 weeks had a positive effect on bone health, as indicated by serum ICTP, with no effect on serum 25(OH)D levels over vitamin D supplementation alone.


  • Open Access

    Impact of Omega-3 and Vitamin D Supplementation on Bone Turnover Markers in Children with Leukemia: Follow-Up During and After Supplementation

    by Lourdes Barbosa-Cortés, Sharon B. Morales-Montes, Michelle Maldonado-Alvarado, Jorge A. Martin-Trejo, Salvador Atilano-Miguel, Emmanuel Jiménez-Aguayo, Fabián I. Martínez-Becerril, Víctor M. Cortés-Beltrán, Atzin V. Hernández-Barbosa, Karina A. Solís-Labastida, et al.

    Background/Objective: In patients with acute lymphoblastic leukemia (ALL), it has been demonstrated that the treatment has a negative effect on bone health. The n-3 polyunsaturated fatty acids (LCPUFAs-ω3) may attenuate bone resorption. We evaluated the effects of LCPUFAs-ω3, vitamin D, and calcium supplementation on bone turnover markers and changes in vitamin D concentrations during 6 weeks of supplementation and 6 weeks post-intervention follow-up in pediatric patients with ALL. Methods: Thirty-six pediatric patients with ALL were randomly assigned to the ω3VDCa group (100 mg/kg/d LCPUFAs-ω3+4,000 IU vitamin D+1,000 mg calcium) or the VDCa group (4,000 IU vitamin D+1,000 mg calcium) for 6 weeks. Blood samples were collected to determine vitamin D (25(OH)D), PTH, ICTP and TRAP-5b (biomarkers of bone resorption) and osteocalcin (OC, a biomarker of bone production) levels at baseline, 6 and 12 weeks after supplementation. The vitamin D analysis was performed using ultra-high-performance liquid chromatography coupled to a mass spectrometer, and PTH and bone turnover markers were measured by ELISA. Results: The 25(OH)D concentration increased in both groups (ω3VDCa group: 19.4 ng/mL vs. 44.0 ng/mL, p< 0.0001; VDCa group: 15.3 ng/mL vs. 42.8 ng/mL, p=0.018) and remained significantly higher at 12 weeks. At 12 weeks, ICTP showed lower concentrations in the ω3VDCa group than in the VDCa group (0.74 ng/mL vs. 1.05 ng/mL, p=0.024). Conclusions: Combined omega-3 and 4,000 IU vitamin D supplementation for 6 weeks had a positive effect on bone health, as indicated by serum ICTP, with no effect on serum 25(OH)D levels over vitamin D supplementation alone.

  • Open Access

    Ácidos grasos poliinsaturados omega-3 en pacientes pediátricos con leucemia linfoblástica aguda

    by Sharon Berenice Morales-Montes, Salvador Atilano-Miguel, María de Lourdes Barbosa-Cortés

    El interés en los ácidos grasos poliinsaturados de cadena larga omega-3 ha aumentado en los últimos años. Diversos estudios sugieren que la suplementación con estos ácidos grasos disminuye el riesgo metabólico, los niveles plasmáticos de triglicéridos y atenúan la pérdida de la masa magra, modulando la respuesta inflamatoria. En adultos con cáncer, los resultados de diferentes estudios que han evaluado los efectos de la administración de estos ácidos grasos sugieren que pueden ser utilizados como adyuvantes durante el tratamiento actuando como agonistas de receptores, modulando diferentes vías moleculares, reduciendo la respuesta inflamatoria, aumentando la eficacia de la quimioterapia y, en consecuencia, mejorando la supervivencia global de los pacientes con cáncer. El papel de la nutrición en el tratamiento onco-hematológico no se ha comprendido lo suficiente, pese a que el estado nutricio es un factor pronóstico modificable. Actualmente, la evidencia que demuestra el efecto de la suplementación con estos ácidos grasos en pacientes pediátricos con leucemia es limitada y reportan beneficios relacionados con la preservación de la masa magra, control de dislipidemias, factores de riesgo cardiovascular y hepatotoxicidad por metotrexate durante la terapia. Por lo tanto, el objetivo de esta revisión es destacar los resultados de los estudios de intervención con estos ácidos grasos realizados en población pediátrica con leucemia linfoblástica aguda publicados hasta el momento.

  • Open Access

    Hipovitaminosis D y marcadores bioquímicos del metabolismo óseo en niños con leucemia

    by Lourdes Barbosa-Cortés, Salvador Atilano-Miguel, Víctor Manuel Cortés-Beltrán, Sharon Berenice Morales-Montes, Jorge Alfonso Martín-Trejo, Jorge Maldonado-Hernández, Juan Manuel Domínguez-Salgado

    La 25 hidroxivitamina D (25(OH)D) desempeña un papel fundamental en el mantenimiento de la salud ósea. El tratamiento del paciente pediátrico con leucemia linfoblástica aguda (LLA), tiene un efecto negativo sobre el metabolismo óseo. describir la frecuencia de hipovitaminosis D y los cambios en las concentraciones séricas de 25(OH)D, marcadores bioquímicos y hormonales del metabolismo óseo entre el diagnóstico y la remisión. estudio de cohorte, longitudinal, prospectivo, en pacientes pediátricos (4-17 años) con diagnóstico de LLA de novo de células B y sin tratamiento previo. Se tomó una muestra de sangre periférica para determinar las concentraciones de 25(OH)D, hormona paratiroidea (PTH), fósforo y calcio iónico. se incluyeron 40 pacientes, se presentaron 7 pérdidas durante el seguimiento, por lo que sólo se analizaron 33. El 91% de los niños presentaron hipovitaminosis D. Observamos un incremento de las concentraciones del calcio iónico con respecto a los niveles basales (1.1 mmol/L frente a 1.2 mmol/L, p = 0.002). El análisis de los Δ de las concentraciones séricas de PTH y 25(OH)D mostró una relación inversa (rho = -0.397, p = 0.024). estos hallazgos confirman una alta frecuencia de hipovitaminosis D. Niveles bajos de 25(OH)D pueden comprometer la absorción de calcio y generar un aumento compensatorio de PTH.

  • Open Access

    Changes in RANKL, OPG, and 25(OH)D Levels in Children with Leukemia from Diagnosis to Remission

    by Salvador Atilano-Miguel, Lourdes Barbosa-Cortés, Rocío Ortiz-Muñiz, Jorge Maldonado-Hernández, Jorge A. Martin-Trejo, Maricela Rodríguez-Cruz, Lourdes Balcázar-Hernández, Karina A. Solís-Labastida, Benito A. Bautista-Martínez, Azalia Juárez-Moya, et al.

    Background: The receptor activator of the nuclear factor-kB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) pathway is a determining pathway in the balance between bone formation and resorption, and disruptions in this complex can affect bone metabolism. Methods: This study analyzes the changes in RANKL, OPG, and 25(OH)D levels; the RANKL/OPG ratio; and other bone turnover markers (BTMs) from diagnosis to complete remission in children with acute lymphoblastic leukemia (ALL). This is a prospective observational cohort study, carried out at the Instituto Mexicano del Seguro Social, Mexico City, including 33 patients (4–17 years) with newly diagnosed B-cell ALL. The patients were treated with the HP09 chemotherapy protocol. Children who had previously been treated with corticosteroids were excluded. A peripheral blood sample at diagnosis and remission was collected to determine the 25(OH)D and BTM concentrations. Results: Increased RANKL (p = 0.001) and osteocalcin (p < 0.001) levels and RANKL/OPG ratio (p = 0.005) were observed at remission, predominantly in the high-risk (HR) relapse and vitamin D deficiency groups. A negative association between RANKL and OPG (r = −0.454, p = 0.008) was observed. Conclusions: we suggest that the RANKL/OPG ratio could serve as a bone remodeling marker in ALL patients.


  • Open Access

    Changes in RANKL, OPG, and 25(OH)D Levels in Children with Leukemia from Diagnosis to Remission

    by Salvador Atilano-Miguel, Lourdes Barbosa-Cortés, Rocío Ortiz-Muñiz, Jorge Maldonado-Hernández, Jorge A Martin-Trejo, Maricela Rodríguez-Cruz, Lourdes Balcázar-Hernández, Karina A Solís-Labastida, Benito A Bautista-Martínez, Azalia Juárez-Moya, et al.

    Background: The receptor activator of the nuclear factor-kB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) pathway is a determining pathway in the balance between bone formation and resorption; disruptions in this complex can affect bone metabolism. Methods: This study analyzed the changes in RANKL, OPG and 25(OH)D levels, the RANKL/OPG ratio, and other bone turnover markers (BTM) from diagnosis to complete remission in children with acute lym-phoblastic leukemia (ALL). This is a prospective observational cohort study. This study was carried out in the Instituto Mexicano del Seguro Social in Mexico City. Thirty-three patients (4-17 years) with newly diagnosed B-cell ALL were included. The patients were treated with the HP09 chemotherapy protocol. Children who had previously been treated with corticosteroids were excluded. A pe-ripheral blood sample at diagnosis and remission was collected to determine the 25(OH)D and BTM concentrations. Results: Increased RANKL (p=0.001) and osteocalcin (p